• Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT JULY 2026

ZZ BPressemeddelelse05.08.2026, 09.00

Zinzino group revenue increased with a total of 20%, compared with the previous year.

The revenue in July for Zinzino's sales markets increased by 20 % and amounted to SEK 313.4 (261.6) million. Faun Pharma's external sales amounted to SEK 2.5 (2.2) million. Overall, the Group increased revenues by 20 % to SEK 315.9 (263.8) million compared with the previous year.

Accumulated revenue for January - July 2026 increased by 22% to SEK 2,174.8 (1,782.0) million.

Revenues were distributed as follows:

Regions,MSEK 26-Jul 25-Jul Change YTD 2026 YTD 2025 Change
The Nordics 24.5 26.1 -6% 182.2 181.5 0%
Central Europe 98.1 76.7 28% 655.8 491.8 33%
East Europe 27.4 31.6 -13% 193.7 218.1 -11%
South & West Europe 49.9 47.2 6% 357.2 309.2 16%
The Baltics 8.7 10.0 -13% 65.2 66.7 -2%
North America 64.4 47.2 36% 465.8 294.7 58%
South America 3.9 0.8 388% 26.6 5.6 375%
Asia-Pacific 34.3 20.1 71% 176.4 169.1 4%
Africa 2.2 1.9 16% 14.5 12.1 20%
Zinzino 313.4 261.6 20% 2,137.4 1,748.8 22%
Faun Pharma 2.5 2.2 14% 37.4 33.2 13%
Zinzino Group 315.9 263.8 20% 2,174.8 1,782.0 22%

Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Portugal, Spain, United Kingdom, Belgium, Ireland, Serbia, Turkey, Canary Islands
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA, Mexico
-South America: Peru, Colombia
-Asia-Pacific: Australia, New Zealand, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand, China, Philippines, South Korea
-Africa: South Africa

For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, dag@zinzino.com
Fredrik Nielsen CFO Zinzino +46 707 900 174, fredrik.nielsen@zinzino.com

Pictures for publication free of charge: marketing@zinzino.com

Certified Adviser: Tapper Partners AB